Previous 10 | Next 10 |
Image source: The Motley Fool. Cellectis SA (NASDAQ: CLLS) Q2 2020 Earnings Call Aug 6, 2020 , 7:30 a.m. ET Operator Continue reading
Cellectis S.A. (CLLS) Q2 2020 Earnings Conference Call August 06, 2020 7:30 AM ET Company Participants Simon Harnest - Vice President-Corporate Strategy & Finance André Choulika - Chairman & Chief Executive Officer Carrie Brownstein - Chief Medical Officer Eric Dut...
Cellectis (NASDAQ: CLLS ) : Q2 Non-GAAP EPS of -$0.68; GAAP EPS of -$0.76 misses by $0.02 . More news on: Cellectis S.A., Earnings news and commentary, Healthcare stocks news, Read more ...
Enrollment ongoing in Phase 1 dose-escalation trial BALLI-01 in r/r B-ALL patients Enrollment ongoing in Phase 1 dose-escalation trial AMELI-01 in r/r AML patients MELANI-01 trial in r/r MM patients on hold; Cellectis is actively working with the FDA to safely resume the cl...
NEW YORK, July 29, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that it will report its financial results for the...
Chimeric antigen receptor T-cell therapies to fight cancer have been around for a decade, but pharmaceutical companies are just beginning to scratch the surface on their potential applications. In a CAR T-cell therapy, a person's T-cells -- part of the immune system -- are modified by implantin...
NEW YORK, July 21, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that Steve Doares, Ph.D., joins Cellectis f...
Nkarta (NASDAQ: NKTX ) had a big IPO, upsizing the number of shares sold to 14M from 10M. It also priced at $18 vs. the expected range of $16-$17. The offering raised $252M. More news on: Nkarta, Inc., Fate Therapeutics, Inc., CRISPR Therapeutics AG, Top stock market news, IPO News, Health...
ObsEva Reports Positive Data from Phase 3 Uterine Fibroids Studies ObsEva SA ( OBSV ) announced positive top line data from its PRIMROSE 1 and 2 studies. PRIMROSE 1 met its primary endpoint at week 24 while PRIMROSE 2 data showed that continued treatment with linzagolix for 52 weeks offe...
NEW YORK, July 06, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS) - André Choulika, Ph.D., Cellectis’ Chairman and CEO, announces that he will focus all his energy on Cellectis’ development activities, and thus, announces his retirement from...
News, Short Squeeze, Breakout and More Instantly...
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transpl...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...